Skip to main content
KYNB
NASDAQ Life Sciences

Kyntra Bio Reports Q1 Results, Extends Cash Runway into 2028, Advances Pipeline

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$6.85
Mkt Cap
$27.518M
52W Low
$4.85
52W High
$222.688
52W Position info
41% above low
Off High info
97% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

KYNB sits 41% above its 52-week low of $4.85.

Summary

Kyntra Bio reported first-quarter 2026 financial results, showcasing a reduced net loss and a strong cash position of $100.3 million, which is expected to fund operations into 2028, alongside positive pipeline advancements.


Key Events · Earnings and Guidance · KYNB

  • Q1 2026 Financial Results

    Reported total revenue of $3.7 million and a net loss of $15.1 million ($3.74 per share), showing improved revenue and a reduced loss compared to Q1 2025.

  • Extended Cash Runway

    Ended Q1 2026 with $100.3 million in cash, cash equivalents, investments, and accounts receivable, providing sufficient funding into 2028.

  • FG-3246 Pipeline Progress

    Phase 2 monotherapy trial in mCRPC is actively enrolling, with interim analysis expected in Q4 2026, following positive investigator-sponsored study results.

  • Roxadustat Phase 3 Advancement

    Finalizing the pivotal Phase 3 trial protocol for LR-MDS after FDA feedback, with trial initiation anticipated in the second half of 2026.


Analysis · KYNB · Life Sciences

This 8-K provides Kyntra Bio's Q1 2026 financial results and a crucial business update. While the company reported a net loss of $15.1 million, it represents a reduction from the prior year. The most significant aspect is the reported cash, cash equivalents, and investments of $100.3 million, which is projected to provide a cash runway into 2028. For a small biopharmaceutical company, securing a long cash runway is critical for operational stability and funding ongoing clinical trials, especially following previous concerns about financial stability and a recent Nasdaq non-compliance notice. Additionally, the company announced positive progress in its key pipeline programs, FG-3246 and roxadustat, with interim analysis for FG-3246 expected in Q4 2026 and Phase 3 trial initiation for roxadustat in 2H 2026.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, KYNB was trading at $6.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $27.5M. The 52-week trading range was $4.85 to $222.69. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

KYNB - Latest Insights

KYNB
Oct 06, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $5.96
Real-time Price: $3.44 info
Change: -$2.52 (-42%) info
Market Cap: $13.929M info
KYNB
Aug 31, 2026, 5:18 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $7.65
Real-time Price: $3.44 info
Change: -$4.21 (-55%) info
Market Cap: $13.929M info
KYNB
Aug 31, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $7.65
Real-time Price: $3.44 info
Change: -$4.21 (-55%) info
Market Cap: $13.929M info
KYNB
Aug 13, 2026, 4:10 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $6.95
Real-time Price: $3.44 info
Change: -$3.51 (-51%) info
Market Cap: $13.929M info
KYNB
Aug 13, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.95
Real-time Price: $3.44 info
Change: -$3.51 (-51%) info
Market Cap: $13.929M info